Overview

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Mirikizumab